Lymphatic metastasis in non‐small cell lung cancer: recent discoveries and novel therapeutic targets

Lung cancer is the 2nd most common and 1st deadliest cancer worldwide [1]. It presents an enormous burden on society in China, because of its high incidence and mortality rate [2, 3]. About 80%-85% of lung cancers are non-small cell lung cancer (NSCLC). Lymphatic metastasis is a critical event in disease progression that influences clinical treatment and determines the prognosis for NSCLC [4]. Unlike the tightly joined smooth muscle cells and pericytes that make up the walls of blood vessels, lymphatic endothelial cells (LECs) of lymphatic capillaries loosely overlap due to the lack of a complete basementmembrane. Due to the high interstitial pressure in tumor tissues and the loose structure of lymphatic capillaries, initial lym-

[1]  A. Navarro,et al.  Characterization of the MicroRNA Cargo of Extracellular Vesicles Isolated from a Pulmonary Tumor-Draining Vein Identifies miR-203a-3p as a Relapse Biomarker for Resected Non-Small Cell Lung Cancer , 2022, International journal of molecular sciences.

[2]  W. Cho,et al.  Lymph node micrometastasis in non-small cell lung cancer. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[3]  Yi-long Wu,et al.  Genomic Evolution of Lung Cancer Metastasis: Current Status and Perspectives , 2021, Cancer communications.

[4]  Ruihua Xu,et al.  Cancer incidence, mortality, and burden in China: a time‐trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020 , 2021, Cancer communications.

[5]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[6]  Tingting Qin,et al.  Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling , 2020, Cancer biology & medicine.

[7]  Qiang Zhou,et al.  Identification of three circular RNA cargoes in serum exosomes as diagnostic biomarkers of non-small-cell lung cancer in the Chinese population. , 2020, The Journal of molecular diagnostics : JMD.

[8]  Wanqing Chen,et al.  Cancer burden of major cancers in China: A need for sustainable actions , 2020, Cancer communications.

[9]  Yan Zhang,et al.  Serum exosomal miR‐378 upregulation is associated with poor prognosis in non–small‐cell lung cancer patients , 2020, Journal of clinical laboratory analysis.

[10]  Yili Yang,et al.  CCBE1 promotes tumor lymphangiogenesis and is negatively regulated by TGFβ signaling in colorectal cancer , 2020, Theranostics.

[11]  Z. Deng,et al.  Exosomal miR-106b serves as a novel marker for lung cancer and promotes cancer metastasis via targeting PTEN. , 2020, Life sciences.

[12]  Zai-lin Yang,et al.  Exploration of Serum Exosomal LncRNA TBILA and AGAP2-AS1 as Promising Biomarkers for Diagnosis of Non-Small Cell Lung Cancer , 2020, International journal of biological sciences.

[13]  R. Fiorotto,et al.  Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. , 2019, Journal of hepatology.

[14]  M. Majima,et al.  Suppression of lymphangiogenesis by soluble vascular endothelial growth factor receptor-2 in a mouse lung cancer model. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[15]  X. Qiu,et al.  CCL21/CCR7 up-regulate vascular endothelial growth factor-D expression via ERK pathway in human non-small cell lung cancer cells. , 2015, International journal of clinical and experimental pathology.

[16]  Yan-wen Yao,et al.  Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice. , 2015, Translational lung cancer research.

[17]  Takashi Takahashi,et al.  Tumor-Derived Interleukin-1 Promotes Lymphangiogenesis and Lymph Node Metastasis through M2-Type Macrophages , 2014, PloS one.

[18]  S. Stacker,et al.  Lymphangiogenesis and lymphatic vessel remodelling in cancer , 2014, Nature Reviews Cancer.

[19]  H. Ji,et al.  Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis , 2012, Proceedings of the National Academy of Sciences.

[20]  Tara Karnezis,et al.  VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. , 2012, Cancer cell.

[21]  K. Alitalo,et al.  Effects of Angiopoietin-2-Blocking Antibody on Endothelial Cell–Cell Junctions and Lung Metastasis , 2012, Journal of the National Cancer Institute.

[22]  Xiao-li Zhang,et al.  RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways. , 2011, European journal of cancer.

[23]  K. Alitalo,et al.  Lymphangiogenesis: Molecular Mechanisms and Future Promise , 2010, Cell.

[24]  A. Hansen,et al.  Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action. , 2006, Blood.

[25]  A. Steiner,et al.  Epidermal growth factor facilitates melanoma lymph node metastasis by influencing tumor lymphangiogenesis. , 2013, The Journal of investigative dermatology.